|Day Low/High||64.75 / 65.33|
|52 Wk Low/High||45.45 / 68.12|
- 98 percent of previously untreated genotype 1b (GT1b) chronic hepatitis C virus (HCV) infected patients without cirrhosis achieved SVR12 in Phase 3b GARNET study1
AbbVie's impressive move is setting the stage for an upside breakout.
The key is to focus on names with steadily growing earnings and dividends.
AbbVie (ABBV) announced on Tuesday that it would partner with BioArctic Neuroscience to develop and commercialize BioArctic's Parkinson's treatments.
A new post-hoc analysis from the pivotal DECIDE study shows that a significantly greater number of people treated with ZINBRYTA TM (daclizumab) achieved no evidence of disease activity (NEDA) compared to those taking...
Year to date, shares of AbbVie are up 7%. With a gigantic patent battle looming, can the stock go higher?
Drug companies like Merck, Pfizer and Johnson & Johnson are spending big bucks on the opposition of Proposition 61.
Cramer is sticking with International Paper and likes Advanced Micro Devices.
This is not the time to sell in a panic, Cramer says.
If and when interest rates go up, this basket of stocks should continue to do well.
AbbVie's (ABBV) stock rating was cut to 'neutral' at JPMorgan this morning.
Here are Thursday's top research calls, including downgrades for Apple, Lululemon Athletica, Nike and Tractor Supply.
Each of these companies pays extremely safe dividends, yields over 2%, and doesn't appear to be extremely overvalued like many other dividend-paying stocks in the market today.
Here's a technical look at how to trade some of the biggest stocks on Wall Street.
When it comes to investing in health care, hedge fund pro John Paulson knows his stuff.
While the public seized on Mylan's price increases for EpiPens, the story of a common drug industry practice - increasing prices ahead of generics entering the market - got lost.
The pharma company has been increasing the price of the epinephrine injector since 2007, so why are people finally taking notice?
Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.
A recent note from RBC Capital on Gilead gained a lot of attention as well as a pickup in call-option purchases.
RBC Capital analysts say this would free 'trapped value' on drug treatments.
Small biotech tanked on weak earnings, but still seems promising.
RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.
A review of earnings for portfolio names, along with upcoming dividend reminders.
Stocks retreat from record highs on Monday as a selloff in health care overshadows a rally in energy.